Millennium Management’s Akebia Therapeutics AKBA Stock Holding History

Millennium Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-101,800	Closed	-$73K	–	6919
2022 Q1	$73K	Buy	+101,800	New	+$218K	﹤0.01%	6273
2021 Q3	–	Sell	-100,000	Closed	-$379K	–	6730
2021 Q2	$379K	Sell	100,000 -50,000	-33%	-$168K	﹤0.01%	5530
2021 Q1	$508K	Buy	+150,000	New	+$540K	﹤0.01%	4814

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Millennium Management's AKBA Position: Q1 2026 in Review

Millennium Management increased its Akebia Therapeutics (AKBA) stake by 44% in Q1 2026, buying an estimated $1M and bringing the position to 2,384,713 shares worth $3.31M. The position accounts for ﹤0.01% of the portfolio, ranked #3381.

Millennium Management first reported a position in AKBA in Q3 2014 and has held it in 44 quarters since. The position peaked at $15.4M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Millennium Management held 2,384,713 shares of Akebia Therapeutics worth $3.31M as of Q1 2026.
Millennium Management bought 731,244 Akebia Therapeutics shares in Q1 2026, an estimated $1M.
Akebia Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3381 holding.
Millennium Management first reported a position in Akebia Therapeutics in Q3 2014 and has held it in 44 quarters since.
Millennium Management's Akebia Therapeutics position peaked at $15.4M in Q3 2017.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.